Intravenous Metoprolol Versus Intravenous Amiodarone in the Prevention of Atrial Fibrillation After Cardiac Surgery

Atrial Fibrillation Clinical Trial

Official title:

Intravenous Metoprolol Versus Intravenous Amiodarone in the Prevention of Atrial Fibrillation After Cardiac Surgery

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00784316
• Other study ID #: KUH5204005
• Status: Completed
• Phase: Phase 4
• First received: October 31, 2008
• Last updated: November 23, 2011
• Start date: August 2007
• Est. completion date: July 2009

Study information

• Verified date: November 2011
• Source: Kuopio University Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Finland: Research Ethics Committee, Hospital District of Northern Savo
• Study type: Interventional

Clinical Trial Summary

The aim of the study is to test the efficiency of intravenous administration of metoprolol versus intravenous administration of amiodarone in the prevention of atrial fibrillation after cardiac surgery.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 316
• Est. completion date: July 2009
• Est. primary completion date: July 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• elective CABG and aortic valve patients in cardiac surgery,

• previous use of betablocker therapy

Exclusion Criteria:

• previous atrial fibrillation or flutter,

• thyroid disease,

• uncontrolled heart failure,

• II or III degree atrioventricular block

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Atrial Fibrillation
• Cardiac Surgery

Intervention

Drug:
• metoprolol, amiodarone
to compare the effectiviness of intravenous administration of metoprolol and amiodarone in the prevention of atrial fibrillation after cardiac surgery

Locations

Country	Name	City	State
Finland	Halonen jari	Kuopio

Sponsors (3)

Lead Sponsor	Collaborator
Kuopio University Hospital	Tampere University Hospital, Vaasa Central Hospital, Vaasa, Finland

Country where clinical trial is conducted

Finland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of atrial fibrillation		48 hours	Yes